FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report - Summary - MDSpire

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report

  • By

  • Mosè Parisi

  • Nicola Molitierno

  • Claudia Alberti

  • Delia Gagliardi

  • Daniele Velardo

  • Giacomo Pietro Comi

  • Stefania Paola Corti

  • June 19, 2026

  • 0 min

Share

Objective:

To report on two cases of severe generalized myasthenia gravis (MG) where early initiation of advanced therapies, specifically FcRn antagonists and C5 complement inhibitors, was associated with rapid clinical stabilization.

Approach:
    Key Findings:
    • Both patients showed significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores following treatment.
    Interpretation:

    Limitations:
    • The report is based on only two cases, limiting generalizability.
    • Further prospective studies are needed to establish optimal criteria and timing for the use of these agents.
    Conclusion:

Original Source(s)

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report

  • by Mosè Parisi, Nicola Molitierno, Claudia Alberti, Delia Gagliardi, Daniele Velardo, Giacomo Pietro Comi, Stefania Paola Corti

  • June 19, 2026

Related Content

Identification of genes associated with cervical intervertebral disc degeneration and immune cell infiltration

Artificial intelligence in neurovascular surgery: advancing diagnosis, treatment, and outcomes

Phytomedicines in preclinical and clinical research on antipsychotics-induced EPS/EPS-like behaviors: therapeutic effects and neurobiological mechanisms